DDN: micro-cap pharmaceutical distributor with limited upside and elevated execution risk
Intrinsic value VND 9,124 vs market VND 9,000 — implied upside 1.4% (confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược - Thiết bị y tế Đà Nẵng (DDN) is a small-cap pharmaceutical and medical equipment company listed on UPCOM with 16,116,383 shares outstanding. The company operates in the Vietnamese pharmaceuticals distribution/retail segment (ICB: Dược phẩm) and generates revenues from medicine and medical-device sales. Reported revenues were VND 1,392.7 bn in 2024 and VND 1,067.9 bn in 2025, after VND 943.4 bn in 2023, reflecting a volatile top line over the last three years.
Luận điểm đầu tư
DDN's valuation implies essentially no margin of safety: the blended intrinsic value per share is VND 9,124 versus the last match price of VND 9,000 (1.4% upside) and model confidence is very_low. Fundamental performance is weak — ROE of 2.0% and ROA of 0.4% (latest) signal low capital efficiency versus typical peers; net profit margin is near breakeven at 0.4% while gross margin is 8.9%. Leverage is high with Debt/Equity of 3.93x, and net debt reported in the DCF inputs is VND 113,412,668,082 (model input).
The DCF/PE blend driving the intrinsic value has notable sanity issues that reduce conviction: the DCF component shows an anomalous dcf_intrinsic of -179.3 (model inputs), while the PE-based raw intrinsic is VND 3,470.8 per share and the blended result after isotonic calibration is VND 9,124. WACC is set at 10.0% with a terminal growth of 4.0% and a fair PE of 13.69. Given the combination of a distorted DCF output, low earnings quality (score 29.5), illiquidity, 0% foreign ownership room and a dominant majority shareholder (Công ty Cổ phần Megram owning 51.01%), the upside is too narrow to compensate for execution and model risk.
Diễn giải định giá
Blended DCF and PE model (70% DCF / 30% PE) with isotonic calibration to produce the intrinsic value.
- WACC 10.0% and terminal growth 4.0% (model_inputs.wacc, terminal_g)
- PE component using fair PE 13.69 and PE cap 25 (model_inputs.fair_pe, pe_cap)
- Large share of terminal value: TV_pct 57.07% of enterprise value (model_inputs.tv_pct)
- Sanity flags: DCF output anomaly dcf_intrinsic -179.3 and sanities ['illiquid','low_earnings_quality']
- Net debt used in valuation: VND 113,412,668,082 (model_inputs.net_debt)
The blended intrinsic of VND 9,124 implies negligible upside to the market price and model confidence is very_low, so the valuation is highly uncertain. The negative DCF output and heavy reliance on the PE-side calibration reduce our confidence in the intrinsic estimate; treat the target as a low-conviction reference rather than a precise fair value.
Các luận điểm cần cân nhắc
- Stable revenue base of VND 1,392.7 bn in 2024 indicates the company can generate scale in its local market.
- Low P/B at 0.7x suggests some asset-backed upside if profitability and ROE can be improved.
- Presence of institutional controlling shareholder (Megram 51.01%) could support strategic stability or consolidation.
- Very low earnings quality score (29.5) and DCF anomaly (dcf_intrinsic -179.3) point to questionable earnings reliability.
- Profitability is weak: ROE 2.0%, net margin 0.4%, EPS VND 254 despite P/E of 35.5x — valuation multiple appears disconnected from fundamentals.
- High leverage with Debt/Equity 3.93x and reported net debt in model inputs increases solvency risk in a downturn.
- Liquidity and marketability risks: avg daily volume ~10,792 shares (2-week) and sanities flag 'illiquid'; foreign_room is 0.0%, limiting demand from foreign investors.
Bối cảnh ngành
The Vietnamese pharmaceutical distribution sector faces margin pressure from competitive pricing and regulatory oversight. VAS accounting and inventory/lifecycle management in pharma can distort short-term earnings — items like trade discounts, returns and inventory provisions are treated differently under VAS versus IFRS and can affect reported margins and earnings quality. State-related policies (SBV credit guidance) and bank asset restructurings (VAMC bonds) can indirectly affect small distributors through working-capital funding availability. Peers in our coverage show a median implied upside of 12.1% — DDN's 1.4% sits well below that peer median, and several top peers display materially higher conviction and upside.
Yếu tố rủi ro
- Low earnings quality (score 29.5) — reported profits may be volatile or contain one-off elements.
- High leverage: Debt/Equity 3.93x increases refinancing and solvency risk if margins compress.
- Illiquidity and zero foreign room (foreign_room 0.0%) — trading constraints may widen bid-ask and hinder price discovery.
- Concentrated ownership: Megram holds 51.01% which can limit free float and minority liquidity; related-party or strategic control risks exist.
- DCF model anomaly: dcf_intrinsic = -179.3 indicates the cash-flow projection or adjustment inputs are unstable.
- Negative recent revenue momentum: Revenue YoY -23.3% (latest) and net profit fell from VND 7.6 bn in 2024 to VND 4.1 bn in 2025.
- Small market cap and UPCOM listing — lower regulatory disclosure and analyst coverage relative to HSX/HNX-listed peers.
Yếu tố có thể tác động
- Improvement in net margin or a sustainable recovery in revenue growth reversing the -23.3% decline would re-rate ROE and EPS.
- Corporate actions by the majority shareholder (Megram) such as capital injection, M&A or a plan to list on a mainboard could unlock value.
- Reduction in leverage or a restructuring that materially lowers Debt/Equity would reduce solvency risk and improve investor sentiment.
Đánh giá dấu hiệu kế toán
No Beneish M-Score is available (mscore null), so there is no explicit manipulation signal from that test. However, earnings quality is low (29.5) and the model's sanity flags include 'low_earnings_quality' and 'illiquid', which together are the primary forensic concerns. Given the DCF anomaly (dcf_intrinsic -179.3) and volatility in reported profits (net profit VND 7.6 bn in 2024 -> VND 4.1 bn in 2025), investors should treat reported earnings with caution and seek supporting detail in cash flow and working-capital notes.
Lịch sử định giá
The model's historical track record across 12 years shows a hit rate of 27.3% (years where >10% upside calls correctly predicted next-year direction), which is materially below a coin-flip. Average realized upside when correct is high (avg_upside_pct 132.9%) but the low hit rate and the current model confidence of very_low suggest the historical performance provides limited comfort for this specific valuation.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.